Form 4: Casdin Capital Increases Stake in 2seventy bio, Inc. (TSVT) Through Open Market Purchases

Casdin Capital, along with related entities and individuals, has increased its holdings in 2seventy bio, Inc. (TSVT) through a series of open market purchases, while also engaging in total return swap agreements.

Summary

• Casdin Capital, LLC, along with related entities and individuals, filed a Form 4 disclosing changes in beneficial ownership of 2seventy bio, Inc. (TSVT) common stock.
• Between March 21 and March 25, 2024, Casdin Partners Master Fund, L.P. purchased a total of 777,377 shares of TSVT common stock through a series of transactions at weighted average prices ranging from $4.9033 to $5.0727 per share.
• These purchases increased the fund's holdings to 1,960,000 shares.
• Eli Casdin was granted 16,600 restricted stock units that vest ratably over three years, starting March 20, 2025.
• Casdin Partners Master Fund, L.P. also holds cash-settled total return swap agreements representing economic exposure to 536,784.15 notional shares of TSVT common stock.
• Eli Casdin, as a managing member of Casdin Capital, LLC and Casdin Partners GP, LLC, and as a director of 2seventy bio, Inc., may be deemed to have indirect beneficial ownership of the reported securities.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The increased investment by Casdin Capital suggests a positive outlook on 2seventy bio's prospects, but the disclaimer of beneficial ownership beyond pecuniary interest tempers the enthusiasm.

Positives

• Increased investment by Casdin Capital signals confidence in 2seventy bio's future prospects.
• The open market purchases demonstrate a willingness to invest at current market prices.
• The acquisition of shares and total return swaps increases Casdin Capital's economic exposure to TSVT.

Management Comments

• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market regarding their investment activities.

Comparison to Industry Standards

• Casdin Capital's investment in 2seventy bio is similar to other instances where investment firms increase their stakes in biotechnology companies they believe have strong growth potential.
• Comparable examples include venture capital firms increasing their positions in early-stage biotech companies or hedge funds taking larger stakes in publicly traded biotech firms with promising clinical trial results.
• The use of total return swaps is a common strategy employed by investment funds to gain economic exposure to a company's stock without directly owning the shares.

Stakeholder Impact

• The increased investment by a major shareholder could positively influence investor confidence.
• The transactions may have a short-term impact on the stock price of 2seventy bio.

Key Dates